Monitoring Critical Quality Attributes with a Peptide-Mapping-Based Multi-Attribute Method

Significance of the topic

Monitoring critical quality attributes (CQAs) of biotherapeutics is essential to ensure safety, efficacy, and lot-to-lot consistency. Multi-attribute methods (MAM) based on peptide mapping and LC/MS offer a consolidated analytical approach that can replace multiple orthogonal assays by simultaneously identifying, localizing, and quantifying a broad set of modifications. A robust, user-friendly MAM workflow that is amenable to method transfer and regulatory-compliant data handling can accelerate routine implementation of MAM in QC laboratories and reduce operational complexity.

Objectives and study overview

This application note demonstrates a practical, compliance-ready MAM workflow for CQA characterization and routine monitoring using trastuzumab as a model monoclonal antibody. Key goals were to: identify and validate attribute-bearing peptides by LC/MS/MS, show site-specific localization of modifications, transfer the validated assay to an MS-only platform for routine QC, and illustrate streamlined data processing using Agilent MAM for OpenLab CDS.

Methodology

Sample stress and preparation:

• Trastuzumab diluted to 5 mg/mL in 50 mM Tris-HCl (pH 7.0) and subjected to accelerated stress (40 °C, 300 rpm). Aliquots taken at 0, 1, 4, 7, 14, and 28 days.
• Denaturation with 8 M guanidine-HCl, reduction with DTT, alkylation with iodoacetamide, buffer exchange using AdvanceBio spin columns, and tryptic digestion (trypsin Gold) at 37 °C for 2 hours. Samples acidified prior to LC/MS.

LC and MS characterization strategy:

• Phase I characterization used LC/MS/MS to identify peptides and localize modifications; Phase II monitoring used MS-only acquisition with targeted extracted ion chromatograms (EICs).
• Peptide mapping concentrated on achieving confident coverage of functional and CDR regions rather than exhaustive full-sequence coverage.

Instrumentation used

Key instruments and software applied in the workflow:

• LC systems: Agilent 1290 Infinity III bio LC.
• Characterization MS/MS: Agilent 6545XT AdvanceBio LC/Q-TOF (auto MS/MS mode) for comprehensive fragmentation and site localization.
• Routine monitoring MS-only: Agilent 6230C TOF LC/MS for targeted, high-resolution MS acquisition.
• Chromatography column: Agilent AdvanceBio Peptide Mapping column (2.1 × 150 mm, 2.7 μm), column temperature ~50 °C, flow 0.25 mL/min, low-organic to high-organic gradient for peptide separation.
• Software: Agilent OpenLab CDS for acquisition, MassHunter BioConfirm for MS/MS-based peptide identification, and Agilent MAM for OpenLab CDS for targeted CQA monitoring and automated EIC integration.

Key results and discussion

Identification and localization:

• LC/MS/MS characterization produced ~89% sequence coverage across heavy and light chains, with complete coverage of functional/critical regions (including CDRs) necessary for confident CQA localization.
• MS/MS fragmentation maps allowed unambiguous assignment of site-specific modifications (for example, site-specific deamidation within peptides), providing a reliable basis for target selection used in the QC assay.

CQAs selected for monitoring:

• Multiple modifications were validated as CQAs, including deamidation at several Asn residues (e.g., N55, N84, N289, N318, N364 on heavy chain and N30, N158 on light chain), isomerization at specific Asp residues (e.g., D102, D252), and oxidation (e.g., M255).
• The workflow supports grouping of related targets and independent quantification of multiple modifications occurring within the same peptide (illustrated by separate quantification of D252 isomerization and M255 oxidation within peptide DTLMISR).

Quantitative monitoring and trends:

• After transfer to the MS-only platform and configuration in MAM for OpenLab CDS, EIC-based quantification produced reproducible results across replicates and captured large dynamic ranges of modification levels.
• All monitored CQAs increased over the stress time course, consistent with expected degradation pathways. Representative trends: N55 (HC) deamidation and N30 (LC) deamidation displayed rapid increases under stress, reaching high relative abundances by 28 days; D102 isomerization and M255 oxidation also rose progressively but to more moderate extents.
• Results were exportable for downstream trend analysis and could be automatically compared to predefined acceptance thresholds in the software.

Benefits and practical applications of the method

The implemented MAM workflow delivers several practical advantages for biopharma QC:

• Consolidation: Replaces multiple orthogonal assays by integrating identification, localization, and quantification of multiple CQAs in a single workflow.
• Throughput and simplicity: Routine QC uses MS-only acquisition with targeted EIC extraction, reducing instrument duty complexity and data-processing burden relative to MS/MS.
• Traceability and compliance: Agilent MAM for OpenLab CDS provides a web-based, user-friendly interface with automated integration, target grouping, threshold checks, and export functionality to support regulatory expectations for data handling.
• Method transferability: Demonstrated transfer from a characterization Q-TOF (6545XT) to a monitoring TOF (6230C) with retained ability to quantify validated CQAs.

Future trends and potential uses

Anticipated developments that will broaden MAM adoption in QC include:

• Improved software ergonomics and regulatory features (audit trails, user roles, electronic records) to streamline qualification and inspection readiness.
• Automation and higher throughput sample preparation to support routine QC pipelines.
• Enhanced new-peak detection and data-mining tools, including machine-learning assisted peak review, to decrease manual review burden while preserving sensitivity to unexpected variants.
• Standardization of MAM validation approaches and cross-lab harmonization to enable regulatory acceptance and broader industry uptake.

Conclusion

This work demonstrates a practical MAM workflow that combines LC/MS/MS characterization for robust CQA identification with MS-only monitoring on a TOF platform for routine QC. The approach provides site-specific localization, reproducible quantification across a wide dynamic range, and a streamlined software environment (Agilent MAM for OpenLab CDS) tailored for regulatory-compliant deployment. The workflow supports efficient method transfer to QC laboratories and offers a scalable path to replace multiple legacy assays with a single, data-rich method.

References

1. United States Pharmacopeial Convention. USP General Chapter <1060> Analytical Data—Interpretation and Treatment. Rockville, MD: USP; 2024.
2. Agilent Technologies. AdvanceBio Spin Columns; Agilent Technologies user guide, publication number 5994-7244EN, 2024.
3. Promega. Trypsin Gold, Mass Spectrometry Grade Technical Bulletin, TB309.